Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood

Fernández‐Avilés, Francesc; Urbano-Ispizúa, Álvaro; Aymerich, Marta; Colomer, Dolors; Rovira, Montserrat; Martı́nez, Carmen; Nadal, E.; Talarn, Carme; Carreras, Enric; Montserrat, Emilio

doi:10.1038/sj.leu.2402854

Cited by 47 publications

(41 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using STR-PCR-based serial analysis of microsatellite regions in short time intervals, it could be shown that patients with rapidly increasing mixed chimerism have the highest risk of relapse. [13][14][15] These reports could be confirmed by others, [96][97][98][99] whereas some studies did not find a correlation between chimerism and relapse. 22,38,100,101 These discrepancies may partly be explained with sampling protocols used in the studies.…”

Section: Hemoglobinopathiessupporting

confidence: 77%

How and when should we monitor chimerism after allogeneic stem cell transplantation?

Bader

Niethammer

Willasch

et al. 2004

Bone Marrow Transplant

180

155

View full text Add to dashboard Cite

Summary:Chimerism analysis has become an important tool for the peri-transplant surveillance of engraftment. It offers the possibility to realize impending graft rejection and can serve as an indicator for the recurrence of the underlying malignant or nonmalignant disease. Most recently, these investigations have become the basis for treatment intervention, for example, to avoid graft rejection, to maintain engraftment and to treat imminent relapse by pre-emptive immunotherapy. This invited review focuses on the clinical implications of characterization of hematopoietic chimerism in stem cell transplantation.

show abstract

Section: Hemoglobinopathiessupporting

confidence: 77%

How and when should we monitor chimerism after allogeneic stem cell transplantation?

Bader

Niethammer

Willasch

et al. 2004

Bone Marrow Transplant

180

155

View full text Add to dashboard Cite

show abstract

“…By using short tandem repeat (STR)-PCR-based serial analysis of microsatellite regions at short time intervals, it could be shown that patients with rapidly increasing mixed chimerism have the highest risk of relapse. 3,9 These reports could be confirmed by others, [10][11][12] whereas some studies did not find a correlation between chimerism and relapse. 13 These discrepancies may partly be explained with sampling protocols used in the studies.…”

Section: Chimerism In Malignant Diseasessupporting

confidence: 78%

Monitoring of post-transplant remission of childhood malignancies: is there a standard?

Bader

Willasch

Klingebiel

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The clinical significance of persistence of hostderived cells is not fully understood, because several factors appear to contribute to chimerism including patient status, underlying diseases, and transplant procedures [19][20][21][22]. Furthermore, differences in sensitivity of assessment methods affect evaluation of clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

Long‐term persistence of host cells detected by X‐chromosome gene‐based assay in patients undergoing gender‐mismatched hematopoietic stem cell transplantation

et al. 2005

View full text Add to dashboard Cite

Using our recently developed human androgen receptor (HUMARA) gene-based chimerism assay, long-term chimerism was investigated in female patients who underwent hematopoietic stem cell transplantation (HCT) with cells from male donors. After restriction digestion of samples, we detected a small number of female-derived cells within a large population of male-derived cells, with a sensitivity from 0.1% to 0.05%. Chimerism was examined in four patients with myeloid malignancies: two patients with acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS), and one patient each with AML M3 and AML M4. All patients underwent myeloablative conditioning regimens and exhibited good clinical results during a median follow-up period of 6.6 years (range, 3.4-7.5 years). Female-derived cells were detected throughout the entire follow-up period in all bone marrow samples, but they became undetectable in the peripheral blood samples of 3 patients. Moreover, the HUMARA band pattern suggests that these residual host cells were normal cells. This study confirms the usefulness of the HUMARA gene-based assay, which showed that patients undergoing HCT frequently show mixed chimerism (MC) for a long period, especially in bone marrow, although the possibility of contamination by host stromal cells cannot be excluded.

show abstract

Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood

Cited by 47 publications

References 45 publications

How and when should we monitor chimerism after allogeneic stem cell transplantation?

How and when should we monitor chimerism after allogeneic stem cell transplantation?

Monitoring of post-transplant remission of childhood malignancies: is there a standard?

Long‐term persistence of host cells detected by X‐chromosome gene‐based assay in patients undergoing gender‐mismatched hematopoietic stem cell transplantation

Contact Info

Product

Resources

About